Targeted Combo Yields PFS of 40 Months in HER2-Positive Breast Cancer

(MedPage Today) -- At the recent American Society of Clinical Oncology (ASCO) meeting, the DESTINY-Breast09 trial drew attention for its impressive first-line results in HER2-positive locally advanced or metastatic breast cancer. The combination...